[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pleural-effusion-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pleural-effusion-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,68,95,118,139,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100643884","ultrasound-assessment-of-diaphragmatic-structure-and-function-in-patients-with-liver-cirrhosis-a-point-of-care-tool-for-predicting-complications-and-sarcopenia-in-limited-resource-settings-100643884",false,"NCT07667608","Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Confirmed diagnosis of liver cirrhosis based on clinical, biochemical, histological, or imaging criteria.\n3. Ability to provide written informed consent in Arabic or English.\n4. For Subgroup A: clinical indication for large-volume paracentesis with an ascitic volume of ≥5 liters.\n5. For Subgroup B: confirmed hepatic hydrothorax or confirmed absence of pleural effusion on ultrasound or chest X-ray.\n6. For Subgroup C: radiologically confirmed HCC by triphasic CT or MRI according to EASL\u002FAASLD diagnostic criteria, with available CT imaging for L3 SMI analysis.\n\nExclusion Criteria:\n\n1. Significant pre-existing primary pulmonary disease (e.g., moderate-to-severe COPD defined as FEV1\u002FFVC \\\u003C70% with FEV1 \\\u003C60% predicted, interstitial lung disease, pulmonary fibrosis) that independently affects diaphragmatic mechanics.\n2. Recent thoracic surgery, thoracocentesis within the preceding 72 hours, or thoracic trauma.\n3. Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, Guillain-Barré syndrome) independently affecting diaphragmatic function.\n4. Active mechanical ventilation at time of enrollment.\n5. Pregnancy.\n6. Inability to achieve adequate ultrasound acoustic windows (e.g., due to extreme obesity or surgical dressings).\n7. Contraindications to paracentesis in Subgroup A (e.g., disseminated intravascular coagulation, bowel obstruction).\n8. Prior or planned liver transplantation within the study period, which would confound longitudinal follow-up.\n9. Refusal or inability to provide informed consent.",true,"ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn how liver cirrhosis affects the diaphragm, the main muscle used for breathing, in adults. The study will measure diaphragmatic thickness, thickening fraction, and excursion using bedside ultrasound and compare these values between patients with cirrhosis and healthy volunteers. The main questions it aims to answer are:\n\nDo patients with cirrhosis show reduced diaphragmatic function compared to healthy adults?\n\nDoes removal of ascitic fluid by paracentesis improve diaphragmatic mechanics?\n\nCan ultrasound measurements of the diaphragm serve as a reliable non-invasive marker of sarcopenia when compared to CT scans?\n\nParticipants will:\n\nUndergo diaphragmatic ultrasound during quiet and deep breathing\n\nProvide clinical and laboratory data related to liver disease severity\n\nIn some cases, have ultrasound repeated before and after paracentesis\n\nFor patients with hepatocellular carcinoma, CT scans will be analyzed to measure muscle mass",[24,25,26,27,28,29],"Cirrhosis of the Liver","Ascites","Pleural Effusion Disorder","Hepatocellular Carcinoma (HCC)","Sarcopenia","Diaphragm Movement","NOT_YET_RECRUITING","2026-06-19",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":20},"2026-08-10",{"date":38,"type":20},"2027-12-10",{"name":40,"class":41},"Assiut University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100601768","dual-function-semirigid-thoracoscopy-versus-rigid-thoracoscopy-for-the-diagnosis-of-pleural-disease-100601768","NCT07114783","Dual-function Semirigid Thoracoscopy Versus Rigid Thoracoscopy for the Diagnosis of Pleural Disease","Dual-function Semirigid Thoracoscopy Versus Rigid Thoracoscopy for the Diagnosis of Pleural Disease: a Randomised Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Patients with unilateral pleural effusion of unclear aetiology after less invasive means of diagnosis;\n3. Fully informed of the purpose and method of the study, agreed to participate in the study, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with PaO2\u002FFiO2 \\\u003C300;\n2. Patients with a tendency for uncontrolled bleeding, unstable cardiovascular status or severe heart failure;\n3. Patients with complete pleural symphysis, where it was not possible to create a pneumothorax, were excluded subsequently;\n4. Patients with refractory cough;\n5. Patients with Eastern Cooperative Oncology Group performance status 4;\n6. Patients did not agree to participate in this study;\n7. Participation in other studies within three months without withdrawal or termination will affect the observation of this study.",{"count":50,"type":20},92,"INTERVENTIONAL",[53],"NA","Medical thoracoscopy (rigid and semirigid) is an effective, safe method for diagnosing and managing pleural diseases. Rigid thoracoscopy demonstrates superior overall diagnostic yield compared to semirigid techniques (flexible forceps\u002Fcryobiopsy) due to its ability to obtain larger, deeper biopsies with rigid forceps. However, diagnostic rates become similar when biopsies are successfully obtained.\n\nLimitations of rigid thoracoscopy include restricted maneuverability (especially in posterior\u002Fmediastinal areas), increased procedural pain from leveraging against ribs and larger trocars, higher sedation requirements, and a steep learning curve for pulmonologists.\n\nTo address these issues, a novel dual-function semirigid thoracoscope (UE FET-680, China) was developed. Its straight working channel accommodates standard rigid biopsy forceps, potentially matching rigid thoracoscopy's diagnostic yield while improving usability. This randomized trial will compare the efficacy and safety of this new device versus conventional rigid thoracoscopy in undiagnosed exudative pleural effusions.",[26],[57,58],"Medical Thoracoscopy","Pleural Disease","2026-06-16",{"date":61,"type":34},"2026-06-22",{"date":63,"type":20},"2026-08",{"date":65,"type":20},"2027-12",{"name":67,"class":41},"China-Japan Friendship Hospital",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100591664","validation-and-clinical-utility-of-the-lung-sliding-index-lsi-for-differentiating-pulmonary-diseases-100591664","NCT06983366","Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases","Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases: A Prospective Case-Control Study","Inclusion Criteria:\n\n* Age 18 years and older.\n* Diagnosed with one of the specified pulmonary diseases, or a healthy control\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to tolerate or undergo a lung ultrasound\n* Extensive chest wall pathology precluding assessment\n* Unscorable \\>2 zones per protocol\n* Withdrawal of consent\n* Mechanically-ventilated patients",{"count":76,"type":20},700,"This upcoming case-control study aims to confirm the Lung Sliding Index (LSI), a new ultrasound score that measures how well the pleura moves, in various lung diseases. The study will check how well the LSI can tell apart different lung diseases (like pneumothorax, interstitial lung disease, COPD, pneumonia, and pulmonary edema), how it relates to signs of disease severity, and how consistent the results are between different operators who have received the same training. Secondary objectives include assessing patient and operator satisfaction and feasibility using validated Likert scales.",[79,80,81,82,83,26,84],"COPD","ILD","Bronchiectasis","Pneumothorax","Pneumonia","Pulmonary Oedema","RECRUITING","2026-04-26",{"date":88,"type":34},"2026-04-30",{"date":90,"type":34},"2025-05-30",{"date":92,"type":20},"2026-08-01",{"name":40,"class":41},1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":51,"phases":103,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":94},"100625206","ultrasounic-elastography-guided-pleural-biopsy-followed-by-as-needed-medical-thoracoscopic-pleural-biopsy-versus-immediate-medical-thoracoscopic-pleural-biopsy-for-the-diagnosis-of-pleural-effusion-100625206","NCT07419620","Ultrasounic Elastography-guided Pleural Biopsy Followed by As-needed Medical Thoracoscopic Pleural Biopsy Versus Immediate Medical Thoracoscopic Pleural Biopsy for the Diagnosis of Pleural Effusion","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Patients with exudative pleural effusion of unknown origin;\n3. Patients with negative pleural fluid cytology results;\n4. Patients who had not undergone pleural biopsy before enrolment.\n\nExclusion Criteria:\n\n1. Significantly bleeding risk, including uncorrectable coagulopathy (such as INR \\>1.5, platelet count \\\u003C50×109 \u002FL) or the need for ongoing anticoagulant\u002Fantiplatelet therapy that cannot be safely paused;\n2. Hemodynamic instability;\n3. Refractory hypoxemia despite supplemental oxygen;\n4. Any severe concurrent illness or cardiopulmonary compromise that, in the investigator's judgment, makes either procedural sedation (for thoracoscopy) or a bedside biopsy (for UEPB) unsafe;\n5. Pleural effusion conclusively identified as a transudate;\n6. Pregnancy or lactation;\n7. Any condition that, in the investigator's judgment, would compromise protocol compliance or follow-up.",{"count":102,"type":20},420,[53],"Brief Summary\n\nThe goal of this clinical trial is to determine whether an initial diagnostic approach using ultrasound elastography-guided pleural biopsy (UEPB) is non-inferior to immediate medical thoracoscopic pleural biopsy in terms of diagnostic yield for obtaining a definitive histopathological diagnosis in patients with exudative pleural effusion of unclear etiology.\n\nThe main questions it aims to answer are:\n\nIs the step-up strategy (UEPB first, reserving thoracoscopy for non-diagnostic cases) non-inferior to immediate medical thoracoscopy in diagnostic yield?\n\nDoes the step-up strategy provide advantages in safety, patient tolerance, hospital stay, and cost-effectiveness compared to immediate thoracoscopy?\n\nResearchers will compare a step-up strategy (initial UEPB, followed by medical thoracoscopy if UEPB is non-diagnostic) versus immediate medical thoracoscopic pleural biopsy to see if the step-up approach achieves comparable diagnostic accuracy while potentially reducing procedure-related burden and healthcare resource use.\n\nParticipants will:\n\nBe randomly assigned in a 1:1 ratio to either the step-up strategy arm or the immediate medical thoracoscopy arm.\n\nIf assigned to the step-up arm: undergo UEPB under local anesthesia; if the biopsy is non-diagnostic, proceed to semi-rigid medical thoracoscopy.\n\nIf assigned to the immediate thoracoscopy arm: undergo semi-rigid medical thoracoscopic pleural biopsy as the initial and sole diagnostic procedure.\n\nProvide tissue samples for histopathological, immunohistochemical, and molecular analyses as clinically indicated.\n\nComplete short-term follow-up at 7 days post-procedure (by telephone or clinic visit) to monitor adverse events and symptom recovery.\n\nIf initially diagnosed with non-specific benign disease or remain undiagnosed, complete a long-term follow-up at 12 months to establish a final diagnosis.",[26],[107,108,109],"Pleural biopsy","Ultrasoinc elastography","Semi-rigid thoracoscopy","2026-02-12",{"date":112,"type":34},"2026-02-19",{"date":114,"type":20},"2026-04",{"date":116,"type":20},"2028-04",{"name":67,"class":41},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":51,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":94},"100572001","pleural-irrigation-with-a-novel-devise-100572001","NCT06727578","Pleural Irrigation With a Novel Devise.","A Pilot Assessment of the Safety and Efficacy of Pleural Irrigation for Retained Pleural Infection Using a Novel Irrigation Device","Inclusion Criteria:\n\n* Retained pleural effusion identified via bedside ultrasound within the first 24 hours after chest tube insertion\n* Patient is contraindicated from receiving intrapleural enzymatic therapy within the first 24 hours after chest tube insertion\n\nExclusion Criteria:\n\n* Non-infectious cause of pleural fluid analysis findings listed above identified (e.g. malignancy)\n* Post-procedural empyema or complicated parapneumonic effusion",{"count":126,"type":20},10,[53],"Single-arm pilot trial of the use of intrapleural saline irrigation to treat retained pleural infections for patients with contraindications to standard of care intrapleural enzymatic therapy.",[26],"2025-07-24",{"date":132,"type":34},"2025-07-28",{"date":134,"type":34},"2025-05-25",{"date":136,"type":20},"2026-07-31",{"name":138,"class":41},"Beth Israel Deaconess Medical Center",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":51,"phases":149,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100596037","confocal-laser-endomicroscopy-assisted-ultrasound-guided-pleural-biopsy-100596037","NCT07040241","Confocal Laser Endomicroscopy Assisted Ultrasound Guided Pleural Biopsy","Diagnostic Yield and Safety of Probe-based COnfocaL LAser Endomicroscopy and Ultrasound-guided Pleural BiOpsy in Diagnosing Patients With Unknown pleuRAl Effusion: a Protocol of a Multicenter, Randomized cONtrolled Trial (COLLABORATION-Ⅱ）","Confocal laser","Inclusion Criteria:\n\n* Adult patients with exudative pleural effusion of unknown origin\n* Patients with negative pleural fluid cytology results\n* Patients diagnosed with a probable malignant pleural effusion but without a definite diagnosis and requiring further pathological evaluation\n* Patients who are fully informed of the purpose and method of the study, agree to participate in the study, and sign an informed consent form\n\nExclusion Criteria:\n\n* Inability or refusal to undergo UGBx\n* Patients with any contraindications for pleural biopsy",{"count":148,"type":20},260,[53],"This study aimed to evaluate the diagnostic yield and safety of confocal laser endomicroscopy and ultrasound-guided pleural biopsy in diagnosing patients with unknown pleural effusion.",[26],[153,154,107],"Pleural effusion","Confocal laser endomicroscopy","2025-06-26",{"date":157,"type":34},"2025-06-27",{"date":159,"type":20},"2025-07-01",{"date":161,"type":20},"2027-07-01",{"name":67,"class":41},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":51,"phases":173,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":94},"100570910","phase-2-evaluating-the-efficacy-and-safety-of-saline-irrigation-as-an-add-on-therapy-for-retained-pleural-infections-lytics--100570910","NCT06713382","Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]","Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections (LYTICS +)","[LYTICS+]","Inclusion Criteria:\n\n* Age ≥18 years.\n* Presence of purulent pleural fluid or pleural fluid analysis with any of the following:\n* pH ≤ 7.2.\n* Glucose \\\u003C 40 mg\u002FdL.\n* LDH \\> 1000 IU\u002FL.\n* Presence of bacterial or fungal organisms on Gram stain or culture.\n* Chest tube placement with less than 200 mL drainage in 24 hours.\n* Indication for IPFT treatment based on treating physician's criteria.\n* Radiographic evidence of septations on chest ultrasound (US) or loculations on low-dose chest computed tomography (CT).\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Pregnant patients.\n* Patients with significant comorbidities that may interfere with the study -outcomes (e.g., terminal malignancy).\n* Complicated sympathetic effusion.\n* Hepatic hydrothorax.",{"count":172,"type":20},96,[174],"PHASE2","The purpose of this protocol is to conduct a pilot prospective non-blind clinical trial to evaluate the efficacy and safety of a novel saline irrigation technique as an adjunct to standard interventions for treating retained pleural infections. Intrapleural fibrinolytic therapy (IPFT) is commonly used for infections not adequately managed with antibiotics and intercostal tube drainage, while saline irrigation serves as an alternative for cases with a high bleeding risk where IPFT is not feasible. The efficacy of saline irrigation combined with IPFT remains unexplored. The hypothesis is that saline irrigation could be an effective and safe addition to IPFT for patients with persistent pleural infections.\n\nThe specific aims of the study include:\n\nDetermine the efficacy of saline irrigation as add-on therapy to IPFT: Compare the clinical outcomes of patients receiving saline irrigation combined with IPFT to those receiving IPFT alone to determine if the addition of saline irrigation offers significant benefits. Outcomes include changes in inflammatory markers, imaging characteristics (echography and CT), volume of pleural fluid drained, chest tube duration, hospital length of stay, and the need for subsequent surgical intervention.\n\nAssess the safety and tolerability of saline irrigation plus IPFT: Compare complications and patient comfort in those receiving saline irrigation combined with IPFT to those receiving IPFT alone.",[177,26,178],"Pleural Effusion Associated With Pulmonary Infection","Pleural Effusions",[180,181,182,183,184],"Pleural Effusion","Thoracentesis","Tissue Plasminogen Activator","DNase","Therapeutic Irrigation","2025-05-21",{"date":134,"type":34},{"date":188,"type":34},"2025-04-10",{"date":190,"type":20},"2026-12-20",{"name":138,"class":41}]